Cargando…
Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676143/ https://www.ncbi.nlm.nih.gov/pubmed/36420113 http://dx.doi.org/10.1016/j.euros.2022.10.018 |
| _version_ | 1784833523748700160 |
|---|---|
| author | Shore, Neal D. |
| author_facet | Shore, Neal D. |
| author_sort | Shore, Neal D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9676143 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96761432022-11-22 Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 Shore, Neal D. Eur Urol Open Sci Letter to the Editor Elsevier 2022-11-16 /pmc/articles/PMC9676143/ /pubmed/36420113 http://dx.doi.org/10.1016/j.euros.2022.10.018 Text en © 2022 The Author https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Letter to the Editor Shore, Neal D. Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title | Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title_full | Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title_fullStr | Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title_full_unstemmed | Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title_short | Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36 |
| title_sort | reply to juan gómez rivas, giorgio gandaglia, and francesco montorsi’s letter to the editor re: neal d. shore, joseph renzulli, neil e. fleshner, et al. enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the enact randomized clinical trial. jama oncol 2022;8:1128–36 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676143/ https://www.ncbi.nlm.nih.gov/pubmed/36420113 http://dx.doi.org/10.1016/j.euros.2022.10.018 |
| work_keys_str_mv | AT shoreneald replytojuangomezrivasgiorgiogandagliaandfrancescomontorsislettertotheeditorrenealdshorejosephrenzullineilefleshneretalenzalutamidemonotherapyvsactivesurveillanceinpatientswithlowriskorintermediaterisklocalizedprostatecancertheenactrandomizedclinicaltrialj |